Veracyte, Inc
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas. Its portfolio includes laboratory-developed tests, in vitro diagnostic products, and biopharmaceutical and other services delivered through its own laboratories and partner channels in the United States and selected international markets.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaGenomic tests performed in Veracyte's laboratories for disease diagnosis and risk assessment.
Distributed test kits and related diagnostic products sold to hospital and laboratory customers.
Licensing, testing, research, development, and manufacturing services for third parties.
Tuotteet
Raportoitu · osuus liikevaihdosta- Testing95,1 %
- Biopharmaceutical and Other1,9 %
- Biopharmaceutical and Other Biopharmaceutical Revenue1,3 %
- Testing Other1,2 %
- Biopharmaceutical and Other Contract Manufacturing and Testing0,6 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Veracyte sells primarily to physicians, hospitals, and laboratories that order or run its diagnostic tests, with reimbursement often determined by third-party payers. It also serves biopharmaceutical and other corporate customers that buy access to data, testing, development, or manufacturing services. In international markets, adoption depends not only on clinical use but also on local coverage, pricing, and reimbursement pathways.
Order Afirma, Decipher, Envisia, and related tests to guide diagnosis and treatment decisions.
Buy Prosigna kits and other diagnostic products for in-house testing workflows.
Influence utilization through coverage and reimbursement decisions for Veracyte tests.
Purchase access to laboratory testing, data, R&D, and manufacturing services.
Adopt tests where local reimbursement and regulatory approvals support use.
Strategia
Veracyte’s strategy centers on expanding adoption of its genomic tests by securing broader payer coverage and reimbursement, while increasing physician penetration and utilization in existing accounts. It also seeks to strengthen its portfolio through new tests, evidence generation, and selective acquisitions or strategic transactions that can extend its reach across the cancer care continuum.
Coverage decisions directly determine utilization, collections, and market access for diagnostic tests.
Test volume depends on ordering behavior by specialists and the depth of use within existing accounts.
Clinical publications, KOL support, and guideline inclusion help defend against competing genomic assays.
A broader menu reduces dependence on a few assays and opens additional disease areas and customer workflows.
Maantiede
2025Veracyte is headquartered in South San Francisco, California and operates a U.S.-centered diagnostics business with international commercialization for selected tests. Its reports highlight reimbursement and regulatory activity in Europe and other foreign markets, and Prosigna is reimbursed in a range of European countries plus Canada, England, Scotland, and Israel. The company also has operations tied to Israel and formerly operated a French subsidiary, reflecting a limited but meaningful international footprint.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Veracyte is exposed to reimbursement, utilization, and regulatory risk because demand for its tests depends heavily on payer coverage and physician ordering patterns. It also faces concentration in a few core products, competition from other genomic testing platforms, and operational risks tied to intellectual property, data privacy, and international compliance.
- Payer reimbursement pressureVaikutus: KorkeaTodennäköisyys: Korkea
Coverage denials, lower reimbursement, or delayed payments reduce utilization and cash collections.
Kohdistuu: Third-party payer mix
- Dependence on Afirma and DecipherVaikutus: KorkeaTodennäköisyys: Kohtalainen
A large share of financial results comes from a small number of core tests, so slower adoption would affect growth.
Kohdistuu: Core diagnostic revenue
- Competitive genomic testing landscapeVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Other companies offer overlapping assays and alternative biomarkers, which can pressure share and pricing.
Kohdistuu - Cybersecurity and data privacyVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company handles sensitive health and patient data, creating liability and business interruption risk.
Kohdistuu: Laboratory and cloud systems
- Intellectual property protectionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Tests rely on proprietary biomarkers, methods, and licensed technology that must be defended.
Kohdistuu - Foreign regulatory and import/export constraintsVaikutus: KeskitasoTodennäköisyys: Matala
International testing may require local approvals and tissue transfer permissions that vary by country.
Kohdistuu: Europe and other non-U.S. markets
Kirjanpito
Harkinnanvaraiset erätRevenue timing depends on whether obligations are satisfied at delivery or through testing/services, affecting quarter-to-quarter comparability.
Vaikutus: Product revenue, biopharmaceutical and other revenue
Claims may be denied or paid later, so estimates of realizability affect reported revenue and receivables.
Vaikutus: Accounts receivable and net revenue
Acquired developed technology and customer backlog are amortized over 10-15 years, affecting cost of revenue.
Vaikutus: Gross margin and operating income
Foreign restructuring and asset impairment created non-cash charges and affected other income.
Vaikutus: Operating results and other income
International operations create translation and remeasurement effects that can move other income and earnings.
Vaikutus: Other income, net
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Myriad Genetics, Inc
MYGN · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier…
Incyte Corporation
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
PharmaCyte Biotech, Inc.
PMCB · Biological Products, (No Diagnostic Substances)
Guardant Health, Inc.
GH · Services-Medical Laboratories
Guardant Health is a precision oncology company built around blood- and tissue-based cancer tests, real-world data, and AI analytics.
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
Päivitetty: 24.9.2026